sur Galimedix, Inc.
Galimedix Therapeutics Completes Phase 1 Study with GAL-101
Galimedix Therapeutics has announced the successful completion of the single ascending dose part of their Phase 1 study of GAL-101. This small molecule, an amyloid beta aggregation modulator, was well tolerated with a favorable safety profile. The study involved 40 healthy volunteers and confirmed GAL-101's suitability for oral administration.
The trial is progressing to the multiple ascending dose phase, expected to conclude in late 2025. Key indications include dry age-related macular degeneration (AMD), glaucoma, and Alzheimer’s disease. The company's Chief Scientific Officer, Hermann Russ, MD, PhD, noted the milestone as vital to GAL-101's development as a potential oral therapy for amyloid beta-related diseases.
Alongside the oral study, a Phase 2 trial of GAL-101 in eyedrop form for dry AMD continues to advance.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Galimedix, Inc.